anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Investigating the molecular biology underpinning the early-stage of traumatic temporomandibular joint (TMJ) ankylosis is crucial for discovering new ways to prevent the disease. This study aimed to explore the dynamic changes of transcriptome from the intra-articular hematoma or the newly generated ankylosed callus during the onset and early progression of TMJ ankylosis.
METHODS: Based on a well-established sheep model of TMJ bony ankylosis, the genome-wide microarray data were obtained from samples at postoperative Days 1, 4, 7, 9, 11, 14 and 28, with intra-articular hematoma at Day 1 serving as controls. Fold changes in gene expression values were measured, and genes were identified via clustering based on time series analysis and further categorised into three major temporal classes: increased, variable and decreased expression groups. The genes in these three temporal groups were further analysed to reveal pathways and establish their biological significance.
RESULTS: Osteoblastic and angiogenetic genes were found to be significantly expressed in the increased expression group. Genes linked to inflammation and osteoclasts were found in the decreased expression group. The various biological processes and pathways related to each temporal expression group were identified, and the increased expression group comprised genes exclusively involved in the following pathways: Hippo signaling pathway, Wnt signaling pathway and Rap 1 signaling pathway. The decreased expression group comprised genes exclusively involved in immune-related pathways and osteoclast differentiation. The variable expression group consisted of genes associated with DNA replication, DNA repair and DNA recombination. Significant biological pathways and transcription factors expressed at each time point postoperatively were also identified.
CONCLUSIONS: These data, for the first time, presented the temporal gene expression profiling and reveal the important process of molecular biology in the early-stage of traumatic TMJ bony ankylosis. The findings might contributed to identifying potential targets for the treatment of TMJ ankylosis.
Halitosis is a common oral condition, which leads to social embarrassment and affects quality of life. Cumulative evidence has suggested the association of tongue-coating microbiome with the development of intraoral halitosis. The dynamic variations of tongue-coating microbiota and metabolites in halitosis have not been fully elucidated. Therefore, the present study aimed to determine the tongue-coating microbial and metabolic characteristics in halitosis subjects without other oral diseases using metagenomics and metabolomics analysis. The participants underwent oral examination, halitosis assessment, and tongue-coating sample collection for the microbiome and metabolome analysis. It was found that the microbiota richness and diversity were significantly elevated in the halitosis group. Furthermore, species from Actinomyces, Prevotella, Veillonella, and Solobacterium were significantly more abundant in the halitosis group. However, the Rothia and Streptococcus species exhibited opposite tendencies. Eleven Kyoto Encyclopedia of Genes and Genomes pathways were significantly enriched in the halitosis tongue coatings, including cysteine and methionine metabolism. Functional genes related to sulfur, indole, skatole, and cadaverine metabolic processes (such as serA, metH, metK and dsrAB) were identified to be more abundant in the halitosis samples. The metabolome analysis revealed that indole-3-acetic, ornithine, and L-tryptophan were significantly elevated in the halitosis samples. Furthermore, it was observed that the values of volatile sulfur compounds and indole-3-acetic abundances were positively correlated. The multiomics analysis identified the metagenomic and metabolomic characteristics to differentiate halitosis from healthy individuals using the least absolute shrinkage and selection operator logistic regression and random forest classifier. A total of 19 species and 39 metabolites were identified as features in halitosis patients, which included indole-3-acetic acid, Bacillus altitudinis, Candidatus Saccharibacteria, and Actinomyces species. In conclusion, an evident shift in microbiome and metabolome characteristics was observed in the halitosis tongue coating, which may have a potential etiological significance and provide novel insights into the mechanism for halitosis.
Autologous Umbilical Cord Blood Mononuclear Cells Therapy any time after the diagnosis of cerebral palsy, doses is 20-30ml (total Mononuclear cells\>1\*10\^7/kg). The infusion speed is 1ml/min.
In this interventional pilot study, we investigated the effects of a modified ketogenic diet (KD) on children with autism spectrum disorder (ASD). We previously observed improved behavioral symptoms in this cohort following the KD; this trial was registered with Clinicaltrials.gov (NCT02477904). This report details the alterations observed in the microbiota, inflammation markers, and microRNAs of seven children following a KD for a duration of 4 months. Our analysis included blood and stool samples, collected before and after the KD. After 4 months follow up, we found that the KD led to decreased plasma levels of proinflammatory cytokines (IL-12p70 and IL-1b) and brain-derived neurotrophic factor (BDNF). Additionally, we observed changes in the gut microbiome, increased expression of butyrate kinase in the gut, and altered levels of BDNF-associated miRNAs in the plasma. These cohort findings suggest that the KD may positively influence ASD sociability, as previously observed, by reducing inflammation, reversing gut microbial dysbiosis, and impacting the BDNF pathway related to brain activity.
The pathophysiology underlying the post-acute sequelae of COVID-19 remains understudied and poorly understood, particularly in healthy adults with a history of mild infection. Chronic neuroinflammation may underlie these enduring symptoms, but studying neuroinflammatory phenomena in vivo is challenging, especially without a comparable pre-COVID-19 dataset. In this study, we present a unique dataset of 10 otherwise healthy individuals scanned before and after experiencing mild COVID-19. Two emerging MR-based methods were used to map pre- to post-COVID-19 brain temperature and free water changes. Post-COVID-19 brain temperature and free water increases, which are indirect biomarkers of neuroinflammation, were found in structures functionally associated with olfactory, cognitive, and memory processing. The largest pre- to post-COVID brain temperature increase was observed in the left olfactory tubercle (p = 0.007, 95% CI [0.48, 3.01]), with a mean increase of 1.75 °C. Notably, the olfactory tubercle is also the region of the primary olfactory cortex where participants with chronic olfactory dysfunction showed the most pronounced increases as compared to those without lingering olfactory dysfunction (adjusted pFDR = 0.0189, 95% CI [1.42, 5.27]). These preliminary insights suggest a potential link between neuroinflammation and chronic cognitive and olfactory dysfunction following mild COVID-19, although further investigations are needed to improve our understanding of what underlies these phenomena.
The study is a Phase II randomized, open label, multicenter trial designed to identify whether sirolimus is a potential alternative to prednisone as an up-front treatment for patients with standard-risk acute GVHD defined according to clinical and biomarker-based risk stratification.

Patients with previously untreated, standard-risk acute GVHD, according to the refined Minnesota Criteria, who are in need of systemic therapy, will have a 5 mL blood sample collected prior to randomization to assess their biomarker Ann Arbor Risk status. Ann Arbor scoring results will be provided 48-72 hours after randomization. Patients will begin their study treatment assignments within 24 hours of randomization. Those with biomarker results of combined AA1/2 risk will continue on their randomized study treatment and will be included for primary endpoint analysis (Day 28 complete or partial response) and all planned study procedures and assessments. In contrast, patients with AA3 biomarker risk and those patients with missing biomarker results may continue on their randomized therapies or start another therapy at their physicians' discretion. In addition, AA3 risk patients and those with missing results will not be considered in primary endpoint analysis, but will be included in a subset analysis.
Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
After anesthesia induction patients received lung recruitment maneuver using pressure-control ventilation with a patient in supine position with 10 cmH2O level of positive end-expiratory pressure PEEP during 180 seconds. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
The invention discloses Chukrasone B for treating immune-inflammation. The Chukrasone B is used for the preparation of medicines for treating the immune-inflammation and is particularly suitable for the preparation of medicines for treating rhinitis. Compared with terfenadine and diclofenac sodium, the Chukrasone B has a definite curative effect. The application of the Chukrasone B in the preparation of the medicines for treating the rhinitis is disclosed by the invention for the first time. As the skeleton type of the Chukrasone B belongs to a bran-new skeleton type and the Chukrasone B has unexpected strong activity on rhinitis treatment, the possibility that other compounds provide revelation does not exist. The Chukrasone B has prominently substantial characteristics and meanwhile has remarkably progressive significance when being used for preventing and treating the rhinitis.
The present invention relates to an oriental herbal medicine composition which has an effect of improving liver functions by comprising active ingredients of Lycium chinense, Chinese quince, Eleutherococcus sessiliflorus, Cornus officinalis, Actinidia polygama, Phragmites australis, green tea, onions, Zizyphus jujuba Mill var. inermis Rehder, Valeriana officinalis L. extract powder, brewers yeast, chicken sternum cartilage powder, honey, betaine, Hovenia dulcis extract powder, and red ginseng; and to a preparation method of the same. The oriental herbal medicine composition comprising Lycium chinense of the present invention comprises: 1-30 parts by weight of Lycium chinense; 1-30 parts by weight of Chinese quince; 1-20 parts by weight of Cornus officinalis; 1-20 parts by weight of betaine; 1-10 parts by weight of red ginseng; 1-10 parts by weight of Hovenia dulcis extract powder; 1-30 parts by weight of honey; 1-30 parts by weight of Actinidia polygama fruits; 1-20 parts by weight of brewers yeast; 1-20 parts by weight of Zizyphus jujuba Mill var. inermis Rehder; 1-20 parts by weight of Phragmites australis; 1-20 parts by weight of green tea; 1-20 parts by weight of Eleutherococcus sessiliflorus; 1-20 parts by weight of Valeriana officinalis L. extract powder; 1-20 parts by weight of chicken sternum cartilage powder; and 1-10 parts by weight of onions. Additionally, the present invention provides a preparation method of an oriental herbal medicine composition comprising Lycium chinense for improving liver functions. According to the present invention, the oriental herbal medicine composition may be beneficially used to improve liver functions by comprising effective components including Lycium chinense, Chinese quince, and Valeriana officinalis L. extract.
The invention discloses a traditional Chinese preparation for treating dental ulcer. The traditional Chinese preparation consists of the following bulk medicaments by weight: 20-30g of white paepnyl root, 20-30g of bamboo leaves, 20-30g of fructus forsythiae, 20-30g of Astragalus mongholicus, 10-20g of rehmannia root, 10-20g of Chinese angelica, 10-20g of rattletop, 5-15g of kudzuvine root, 5-15g of Tuckahoe and 5-15g of eupatorium. The preparation method comprises the following steps: smashing the bulk medicaments, screening with a 200-mesh sieve and evenly mixing so as to obtain the traditional Chinese preparation. When administrated, the traditional Chinese preparation is taken by oral, and the dental ulcer can be cured for two to four days. The traditional Chinese preparation disclosed by the invention has the effects of clearing heat and detoxifying, tonifying spleen and resolving dampness, tonifying the spleen and kidneys and nourishing heart and relieving uneasiness and mainly cures the dental ulcer. 105 patients are treated, wherein 102 patients are cured, and effective rate reaches above 97%. The traditional Chinese preparation has a treatment effect on various types of dental ulcer, especially, has a good treatment effect on light dental ulcer; and used bulk medicaments are available, and treatment cost is low.
FIELD: medicine; particularly, transplantology. SUBSTANCE: invention is based on improvement of traditional technology of clinical transplantation of parenchymatous organs on vascular-duct crus where deliberately included into removed organocomplex from donor organism are the main own associated units on postganglionic connections and their supplying vessels and by surgical reefferention of transplant neuroganglions by recipient perivascular vegetative plexuses and implantation reinnervation of the transplanted organ by terminals of recipient nerves after formation of traditional abastomosis in zone of transplantation, partial preservation of own nervous system of graft is attained and effective restoration of its innervation lost as a result of removal from the donor organism. All this considerably increases structural-functional full-value of transplanted organ, its acute rejection is prevented under conditions of use of considerably reduced doses of immunosuppressing preparations, and terms of full-value crisisless functioning of transplant increase to reduce number of post-transplantation complications and to improve recipient life. The method is developed and realized in the course of experimental transplantation of kidneys, pancreas, lungs and liver of 96 mongrel dogs. Possibility of technical realization on human organs is tested and demonstrated in the process of imitation transplantations of kidneys and pancreas on 29 corpses of men and women. Clinical approbation is effected in the center of kidney transplantation on 11 recipients with terminal kidney insufficiency prolonged by hemodialysis. EFFECT: higher structural-functional full-valve of transplanted organ and satisfactory results of clinical transplantation of parenchymatous organs due to effective restoration of their innervation.
PCT No. PCT/GB96/00776 Sec. 371 Date Oct. 8, 1997 Sec. 102(e) Date Oct. 8, 1997 PCT Filed Apr. 1, 1996 PCT Pub. No. WO96/31602 PCT Pub. Date Oct. 10, 1996A proteinaceous particle comprises a capsid enveloped by ecotropic Murine Leukemia virus envelope proteins characterized in that a heterologous peptide which binds to a non-murine cell is inserted in, entirely replaces, or replaces a portion of the native Ser-Gly-Gly-Ser-Ser-Pro-Gly of the VRA region of said envelope proteins. A method for preparing a plurality of such proteinaceous particles comprises expressing within a host cell (i) self-assembling capsid proteins, (ii) Murine Leukemia virus envelope proteins, said ENV proteins modified as defined, and optionally, (iii) packageable RNA, and then culturing the host cells and harvesting the resultant budded particles.
Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -7 to 100 and high dose sirolimus PO on days -4 to 7, Patients undergo mobilized allogeneic PBSC on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
Radical prostatectomy patients will undergo an MRI prior to their scheduled surgery. Ex vivo imaging will be done on prostates once removed. Results from the final pathology with be compared with results of imaging to determine the accuracy of the image analysis in cancer localization and staging.

Brachytherapy patients will undergo an MRI prior to their scheduled procedure. Two areas of suspected cancer and two areas without suspected cancer will be prospectively identified based on the MRI imaging. At the time of brachytherapy, transrectal needle biopsies will be obtained from the previously identified areas. The needle cores will be reviewed by study pathologist to determine the accuracy of the image analysis in cancer localization and staging.
OBJECTIVE: To describe the treatment outcomes of locally advanced cervical cancer managed with neoadjuvant chemotherapy (NACT) plus radical surgery at a gynecology oncology center in Ethiopia.
METHODS: This was a retrospective descriptive study of management of locally advanced cervical cancer (LACC) at St. Paul's Hospital Millennium Medical College (Ethiopia) over 5 years. Data were collected by reviewing patient records. Data were analyzed using SPSS version 23. Simple descriptive analysis was employed to analyze clinical, histologic, and treatment outcomes of LACC managed with NACT+ radical surgery. Frequency and proportions were used to present the results' significance.
RESULTS: A total of 98 patients were analyzed. One-third (31.6%) of cervical cancer patients with locally advanced disease were operable after neoadjuvant chemotherapy. Out of this, nodal metastasis was found in 2 patients (all pelvic lymph node metastasis). Disease recurrence within 2 years was 3% (1 recurrence within 6-12 months and 2 recurrences at 12-24 months).
CONCLUSION: This study supports utilization of NACT plus radical surgery for locally advanced cervical cancer, where chemoradiation is not readily available. Our findings imply that this treatment modality is a life-saving alternative treatment in a low-income setting, which is often married by shortage or unavailability of radiotherapy at the needed time before disease progression ensues.
This case report presents a rare case of infantile nystagmus syndrome (INS) in which the direction of infantile nystagmus (IN) was vertical. A 66-year-old woman was referred to our department for investigation of abnormal eye movements. She showed a disordered field of view with a homonymous hemianopia in the lower left quadrant and vertical gaze-evoked nystagmus, but there were no other abnormal neurological findings. She did not complain of an oscillopsia. Imaging revealed that the cause of hemianopia was atrophy and low cerebral blood flow in the right occipital lobe. The vertical nystagmus became strong when attempting to fixate to stationary targets. A reversed optokinetic nystagmus response was observed in the vertical optokinetic nystagmus test. From these eye movements, we diagnosed her nystagmus as vertical IN. Patients with INS see everything by saccades. IN consists of the alternate appearance of saccades and preceding slow eye movements. For these eye movements, a wide visual field is necessary. In this case, vertical IN was caused by the wider vertical than horizontal visual field resulting from homonymous hemianopia. Therefore, the direction of IN is horizontal in most patients with INS because their horizontal visual field is the widest field.
PURPOSE:To obtain a vasoactive intestinal polypeptide (VIP) analog, having the activity equal to or higher than that of VIP which is a polypeptide hormone expectable as a bronchodilator and a therapeutic agent for impotence and readily mass-producible by a fermentation method. CONSTITUTION:A peptide is mass-produced by using a fermentation method. In the process, the objective peptide in the form of several molecules linked through methionine is effectively developed. If the resultant peptide is chemically cleaved with cyanogen bromide, homoserine is produced in the C-terminal. The aforementioned invention relates to a substance of L-leucine VIP-Hse producible in the above-mentioned form and uses as a bronchodilator and a therapeutic agent for impotence. Although amino acids having amide or positive electric charges at the C-terminal have hitherto been considered essential to developing the activity of the VIP, it was difficult to efficiently produce the aforementioned amino acids by the fermentation method. The L-leucine VIP-Hse of this invention can extremely efficiently be produced by the fermentation method and medicines can efficiently be supplied at a lower cost than that of conventional VIP.
The present invention relates to the use of one or a combination of the phytocannabinoids cannabidiolic acid (CBDA), cannabidivarin (CBDV), and tetrahydrocannabinol (THC) for use in the treatment of a neurodegenerative disease or disorder. In particular the neurodegenerative disease is amyotrophic lateral sclerosis (ALS). The phytocannabinoids may be used in combination with medication used or tested in the treatment of ALS, such as riluzole, edaravone, olexisome, talampanel or ceftriaxone. Preferably THC is used with olexisome. In one embodiment the phytocannabinoid is present as an extract of the cannabis plan, such as a botanical drug substance (BDS). The phytocannabinoid may be present as a highly purified, isolated or synthetic cannabinoid.
Carcinogenicity studies have not been conducted with afatinib.

A marginal response to afatinib was observed in a single tester strain of a bacterial (Ames) mutagenicity assay. No mutagenic or genotoxic potential was identified in an in vitro chromosomal aberration test at non-cytotoxic concentrations as well as in the in vivo bone marrow micronucleus assay, the in vivo Comet assay, and an in vivo 4-week oral mutation study in the Muta™ Mouse.

In a dedicated fertility study, male and female rats received afatinib daily by oral administration at doses of 4, 6, or 8 mg/kg. In males at doses of 6 mg/kg (approximately equal to the exposure by AUC in patients at the recommended human dose of 40 mg daily) or greater, there was an increase in the incidence of low or no sperm count, though overall fertility was not affected; decreases in sperm count were supported by findings of increased apoptosis in the testes and atrophy in the seminal vesicles and the prostate in general toxicology studies. In females at the high dose of 8 mg/kg (approximately 0.63 times the exposure by AUC in patients at the recommended human dose of 40 mg daily), there was a mild decrease in the number of corpora lutea along with a mild increase in post-implantation loss due to early resorptions. In a 4-week general toxicology study, female rats had decreases in ovarian weights at all dose levels; organ weight had not fully recovered by the end of a 2-week recovery period.
In myocardial infarction, ischemia-reperfusion injury (IRI) poses a significant challenge due to a lack of effective treatments. Bilirubin, a natural compound known for its anti-inflammatory and antioxidant properties, has been identified as a potential therapeutic agent for IRI. Currently, there are no reports about proteomic studies related to IRI and bilirubin treatment. In this study, we explored the effects of bilirubin nanoparticles in a rat model of myocardial IRI. A total of 3616 protein groups comprising 76,681 distinct peptides were identified using LC-MS/MS, where we distinguished two kinds of protein groups: those showing increased expression in IRI and decreased expression in IRI with bilirubin treatment, and vice versa, accounting for 202 and 35 proteins, respectively. Our proteomic analysis identified significant upregulation in the Wnt and insulin signaling pathways and increased Golgi markers, indicating their role in mediating bilirubin nanoparticle's protective effects. This research contributes to the proteomic understanding of myocardial IRI and suggests bilirubin nanoparticles as a promising strategy for cardiac protection, warranting further investigation in human models.